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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an 
abnormal CAG expansion in exon 1 of the huntingtin (HTT) gene. Given its genetic basis it is 
possible to study patients both in the pre-manifest and manifest stages of the condition. While 
disease onset can be modelled using CAG repeat size, there are no easily accessible biomarkers 
that can objectively track disease progression. Here, we employed a holistic approach using 
spectral profiles generated using both Surface-enhanced Raman Spectroscopy (SERS) and 
Raman Spectroscopy (RS), on the serum of healthy participants and HD patients covering a wide 
spectrum of disease stages. We found that there was both genotype- and gender-specific 
segregation on using the full range in the fingerprint region with both SERS and RS. On a more 
detailed interrogation using specific spectral intervals, SERS revealed significant correlations 
with disease progression, in particular progression from pre-manifest through to advanced HD 
was associated with serum molecules related to protein misfolding and nucleotide catabolism. 
Thus, this study shows the potential of Raman spectroscopy-based techniques for stratification of 
patients and, of SERS, in particular, to track disease status through provision of ‘spectral’ 





Huntington’s disease (HD) is an inherited autosomal dominant disorder caused by an expanded 
CAG gain-of-function mutation in the HTT gene. HD typically affects people in mid-life and 
leads to progressive motor, cognitive, and affective problems, along with weight loss and 
circadian rhythm disturbances. HD is currently incurable and normally runs a clinical course 
over 20 years in most patients. While a genetic test exists to ascertain whether patients carry the 
mutation, there are currently no accurate ways to mark disease onset. At the present time, 
diagnosis is based on the presence of motor signs in the right genetic context, although moves 
are afoot to try and refine this given that a number of non-motor problems can be seen ahead of 
any motor abnormalities in many HD patients1-3 and animal models.4 Such cognitive and 
psychiatric impairments are associated with structural3 and functional connectivity changes using 
MRI.5,6 While these measures are starting to be used in clinical trials, the cost and inconvenience 
associated with such imaging is not inconsequential, especially as with time chorea (which 
consists of dance-like involuntary movement) develops in most patients that can degrade the 
quality of the scans so obtained. Thus, alternative simpler disease biomarkers have been explored 
in HD, including those using blood. Venepuncture is a simple procedure but previous attempts 
looking for specific serum molecules to track HD have proven unsuccessful. For instance, the 
level of brain-derived neurotrophic factor (BDNF) is tightly controlled to wild-type (WT), but 
not mutant HTT,7 and so unsurprisingly neither the level of BDNF mRNA nor protein in the 
plasma reliably tracks HD progression.8 Another approach looked at the degree of fragmentation 
of mutant Huntingtin protein in peripheral immune cells using time-resolved Förster resonance 
energy transfer, but repeated measurements on a single sample produced considerable 
variability.9 It has been demonstrated more recently that the level of neurofilament light chain in 
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the blood, which is elevated as neurodegeneration proceeds, is a potential biomarker to track the 
onset and progression of HD.10 However, this marker simply reflects cell loss and so is raised in 
other neurological events including ischemic stroke and Alzheimer’s disease, and as such does 
not necessarily track HD per se.11,12 
Given all this, we sought to investigate whether we could use recent advances in techniques 
based on Raman scattering to develop a new serum biomarker approach in patients with HD.13 
Spontaneous Raman Spectroscopy (RS), in particular, is increasingly being researched for 
applications in medical diagnostics using biofluids, cell and tissue samples due to its high 
chemical specificity and capacity to reveal molecular information.14,15 RS is a sensitive, label-
free, and non-destructive optical method, which measures the light inelastically scattered by 
intrinsic molecular vibrations in a specimen. The measurement yields a ‘spectral fingerprint’ 
corresponding to the molecular and biochemical composition of the sample. Practically the 
measurement is simple to undertake- for example a droplet of blood serum (Fig. 1A) is 
interrogated with a laser to give a Raman spectrum (blue spectrum, Fig. 1B). Peaks in the 
resulting spectra correspond to information from molecular constituents in the serum, thereby 
generating unique signatures for them.  
While spontaneous Raman spectroscopy provides a characteristic ‘fingerprint’ of a sample, 
signals can be weak. For this reason, the optical properties of nanomaterials can be used to 
produce stronger signals, which is called surface-enhanced Raman Spectroscopy (SERS). SERS 
uses the enhancing effect of nano-scale metals, typically ‘coinage’ metals and materials such as 
gold nanoparticles (AuNPs), as these interact with the incident light and nanostructure (see SERS 
in Fig. 1A). Thus, AuNPs can be added as an assay reagent before the measurement and because 
this enhancing effect is locally confined to molecules within proximity of the AuNPs, the 
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obtained SERS spectrum (black spectrum, Fig. 1B) mainly reflects contributions from these 
molecules.16-18 
Both RS and SERS have been used previously to measure serum analytes including glucose, 
cholesterol, triglycerides, urea and albumin.14,19 Furthermore, Raman-based techniques have 
been used successfully in a variety of medical conditions including asthma,20 neurodegenerative 
diseases,13,21,22, malaria,14 as well as head-and-neck,23 nasopharyngeal,24 breast,25,26 liver,27 and 
colorectal cancers.28 RS may also be a useful diagnostic tool for Alzheimer’s disease using 
patient serum.22,29 In HD, RS has previously been used to study fibroblasts from patients,30,31 
although its potential to assess disease states or to provide a biomarker has never been explored. 
However, it would have an obvious advantage when employed in this way as mutant huntingtin 
(mHTT) affects multiple pathways in multiple types of cell systems and organs,32 and as such 
RS/SERS could be used to identify HD-specific “signatures” rather than single biomarker 
molecules. This is likely to better reflect the complete range of cell autonomous and non-cell 
autonomous abnormalities found in this neurological condition.   
We therefore acquired Raman and SERS spectra in a cross-sectional cohort of HD patients and 
control participants (n=62) and applied both a principal component (PCA) and linear 
discriminant analysis (LDA) to interrogate our high dimensional dataset. Multivariate techniques 
such as PCA and LDA are widely used in biomedical RS/SERS due to the complexity of spectral 
data sets and have found application in cellular16,18,33 and tissue analysis including in 
blood/serum for diagnosis. 34-37 Using PCA/LDA on acquired spectra we found that SERS is able 
to detect, with a higher specificity than RS, disease stages in line with clinical assessments. In 
addition, we also found that there were specific spectral features to the HD samples due to 
changes in serum molecules that are related to protein misfolding and nucleotide catabolism.  
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In summary, we have shown the feasibility of obtaining spectral biomarkers by Raman 
spectroscopy-based techniques and SERS in HD patients and that this approach could potentially 
play an important role in the early diagnosis of HD and its treatment with disease-modifying 
therapies. 
RESULTS AND DISCUSSION 
While the analysis of bio-fluid samples is relatively straightforward for RS, optimization is 
essential for SERS analysis due to the use of aggregated AuNPs (ESI Fig. S1). We first 
optimised and validated our SERS methodology using cortical homogenates and serum samples 
from female R6/2 mice: a well-known transgenic murine model of HD (Fig. 2).4,38,39 In R6/2 
mice (CAG repeat size 141-157), neurological abnormalities are observed around 7-8 weeks of 
age and progressively worsen until about 12-13 weeks of age, when they are euthanised due to 
major weight loss.39  
We first showed that there was (as expected) accumulation of mutant Huntingtin aggregates in 
cortical (brain) homogenates of R6/2 mice using agarose gel electrophoresis (AGERA) with the 
MW8 antibody (Fig. 2A). The SERS data was then compared with WT littermates using PCA 
and LDA (ESI Table S1, ESI Fig. S2). Using this approach, we found that the first principal 
component (PC1) and linear discriminant scores (LD1) were sufficient for genotype 
classification into WT and HD, respectively. A significant (p < 0.001) segregation between PC1 
scores in both groups was associated with disease progression (Fig. 2B). This signature was 
characterised by dominant spectral changes in those peaks assigned to proline (993 and 1070 cm-
1) and β-sheet protein conformation (955, 1020 and 1086 cm-1). Furthermore, our data showed 
that even at 3 weeks of age when the R6/2 mice and WT littermates are clinically 
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indistinguishable,33 SERS was already capable of genotype classification (ESI Table S2). In 
contrast to brain homogenates, with serum samples PCA alone was not able to provide enough 
segregation (ESI Fig. S2B) and it was only when applying both PCA-LDA that we were able to 
achieve a significant segregation of the LD1 scores with disease progression using serum 
samples (Fig. 2C) (p < 0.001). All of this thus supported the potential application of using SERS 
to study HD patient serum. 
To study the application of RS/SERS results in clinical specimens, we began by analyzing the 
stability of serum samples and the reproducibility of the spectral results under different storage 
conditions. We found that prolonged storage at 4˚C (> 2 days) affected the reproducibility of RS 
measurements, while SERS spectra remained consistent when the samples were stored at either 
4˚C (≥ 15 days) or frozen and then thawed (ESI Fig. S3, ESI Table S3). PC scores of RS/SERS 
spectra from serum samples were compared between HD patients (nMale-HD = 27 and nFemale-
HD = 20) and healthy participants (nMale-ctrl = 5 and nFemale-ctrl = 10) (ESI Table S4). For the RS 
data (Fig. 3A), PC1 and PC2 scores revealed a significant distinction between HD patients and 
healthy participants (PC1: pmale HD-ctrl = 0.003, PC2: pmale HD-ctrl = 0.001, pfemale HD-ctrl = 0.001). For 
SERS (Fig. 3B), there was a significant genotype effect only in male participants in the PC2 
direction (PC2: pmale HD-ctrl = 0.02). While these results were generated using the full spectral 
range, it is better to identify specific features in the spectral intervals which are the best 
classification discriminators and relate to the molecular basis of HD pathology. We therefore 
sub-grouped the spectral data into intervals of 50 cm-1. Using RS, HD patients could be clearly 
distinguished from healthy participants using the spectral region between 300-500 cm-1and 600-
1650 cm-1, with the most significant distinction observed for the spectral region of 600-800 cm-1 
(p < 0.01, Fig. 3C). For SERS, we found a significant distinction between all HD patients (male 
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and female) and healthy participants in the 400-1200 cm-1 range, with the most significant 
distinction being found between 750-800 cm-1 (p < 0.01, Fig. 3D).  
To better characterise the molecular changes, the mean (Fig. 4A-B), standard deviation (Fig. 
4C-D) and the difference spectra (Δ in Fig. 4E-F) were calculated for both RS and SERS spectra. 
As the intensity of the difference spectra (black line in Fig. 4E-F) was smaller than the respective 
standard deviation, we sought to use the more robust PCA-LDA approach to generate spectral 
LD loadings (rainbow-coloured line in Fig. 4E-F). The pattern of LD loadings and the difference 
spectra are highly consistent, although their intensities differ. The coloured line represents the 
explained variance of the PC1 scores (stepwise for 20 cm-1 intervals) specific to spectral peaks in 
the LD loadings (Fig. 4E-F, red to blue: 100% to 0% explained variance). The explained 
variance of RS only exceeds 90% in the range of 950-1750 cm-1, while it covers most of the 
spectrum (400-1800 cm-1) for SERS (Fig. 4E-F). 
To determine if such spectral differences correlated with clinical measures, we next grouped 
correlated PC1 scores for intervals (each 50 cm-1) of the RS (Fig. 5) and SERS spectra (Fig. 6) to 
a range of standard clinical parameters in the HD patients including: i) age, ii) independence 
score (Indp), iii) CAG repeat size (CAG), iv) disease burden score (DB), v) functional 
assessment score (FA), vi) total functional capacity score (TFC), as well as vii) total Unified 
Huntington’s Disease Rating Scale (UHDRS) motor score (see Experimental section). 40-42 Since 
some clinical assessment scales show linear correlation, for instance the DB is a function of age 
and CAG repeat size,40 linear regression of the estimated means (post-hoc ANOVA) of grouped 
PC1 scores from HD patients was computed and the adjusted R2 (aR2) was used to correlate 
spectral regions and clinical parameters (Fig. 5 and Fig. 6, and summarised in ESI Fig. S4).  
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PC1 scores of serum RS showed a high correlation, that is, aR2 > 0.90 only in some spectral 
regions relative to the patient’s age, CAG and TFC (Fig. 5). We found that the influence of 
patient age on the PC1 scores of RS spectral ranges are negligible, with the exception of the 
region of 650-700 cm-1 (aR2Age = 0.91) and 1750-1800 cm
-1 (aR2Age = 0.98) with significant 
peaks at 655 and 692 cm-1, in line with the age-related features assigned previously to C-S 
stretching and twisting modes in proteins, respectively.43 This therefore provides the basis for 
distinguishing spectral changes specific to HD from those related to age. The CAG repeat length 
determines in part the age of onset and less so the rate of progression in HD44,45 and, in 
combination with the patient’s age, the DB score can be computed. PC1 scores of RS showed a 
linear correlation with CAG size only between 300-350 cm-1 and 1750-1850 cm-1 with an aR2CAG 
of 1.00 and 0.97, respectively, and with DB in the range of 1600-1650 cm-1 (aR2DB = 0.93). 
For SERS, PC1 scores showed a high correlation (aR2 > 0.95) to Indp, CAG, DB, FA, TFC 
and UHDRS scores (summarised in ESI Fig. S4 and ESI Table S5). In particular, both CAG size 
and DB correlated with PC1 scores in the SERS spectra (Fig. 6, ESI Fig. S4 and ESI Table S5) in 
the same regions, particularly in the region of 500-600 cm-1 (aR2CAG = 0.97 and aR
2
DB = 0.86) 
and 1000-1100 cm-1 (aR2CAG = 0.94 and aR
2
DB = 0.96). The overlapping SERS regions correlated 
to CAG repeat length and DB scores, which was not found with the RS data, suggesting that 
there are HD-associated molecules in the serum, which although present at a very low 
concentration, have an affinity for gold nanoparticles. Characteristic peaks associated with these 
intervals are at 640, 996, 1022 and 1120 cm-1, which are assigned to phenylalanine (996 cm-1) 
and uric acid, respectively (ESI Table S6). Interestingly, serum levels of uric acid have been 
linked to catabolism46 that has been described as a feature of HD in some studies, including an 
earlier metabonomic study from our group.47,48 Additionally, DB scores correlated strongly 
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(aR2DB > 0.99) to the PC1 scores of SERS in the region of 700-750 cm
-1. This interval shows a 
characteristic peak at 720 cm-1, which can be assigned to DNA/RNA (adenine) and has 
previously been shown to be a diagnostic marker for diseases such as cancer and other systemic 
metabolic disorders.49 
The UHDRS was developed to provide a standardised assessment of clinical features and 
progression of HD in patients. It includes motor and functional assessments, evaluation on the 
level of independence of patients, and a measure of functional capacity.41 A UHDRS motor score 
of ≥ 5 is usually considered diagnostic of disease state. We therefore correlated UHDRS motor 
scores to PC1 scores in manifest (UHDRS ≥ 5) and pre-manifest (UHDRS < 5) HD patients as 
well as healthy participants. While no correlation was observed between UHDRS scores and PC1 
scores in RS, we found a linear correlation in the range of 1200-1300 cm-1 and 1600-1700 cm-1 
for SERS (both aR2UHDRS = 0.91, Fig. 6) and combining the data from both regions improved the 
correlation (Fig. 7A, aR2UHDRS = 0.97). RS/SERS data contained samples from male and female 
participants as all three intervals did not show a significant segregation with gender. The effect 
of genotype on motor impairments, in particular the transition from pre-manifest to manifest, 
could only be revealed using a supervised PCA-LDA approach on SERS data classed as control 
vs HD (Fig. 7B). UHDRS vs LD1 scores showed a clear distinction (pcontrol-manifestHD < 0.001) 
between the control participants and manifest HD groups. The pre-manifest HD group (UHDRS 
motor < 5) did not show clear segregation from the controls (pcontrol-premanifestHD = 0.25) nor the 
manifest HD groups (ppremanifest-manifestHD > 0.92), but appeared to occupy a transitional state. 
These group segregations, in both the PC and the LD space, were based on significant peaks in 
the region of 1200-1300 cm-1 and 1600-1700 cm-1 (Fig. 6 and UHDRS in ESI Table S6). These 
bands were assigned to amide III and amide I,50 respectively, giving important structural 
 11 
information on the protein structure. The peak at 1245 cm-1 is mainly assigned to the C-C and C-
N stretching modes in β-sheet protein secondary structures.51 Complementarily, the peak at 1667 
cm-1 in the amide I band originates from the C=O stretching mode in β-sheets.51,52 These two 
bands suggest a higher content of β-sheet protein structures present in the HD sera compared to 
healthy controls, in line with previous reports on the presence of mutant Huntingtin aggregates in 
the patient blood.53 Overall, our data suggested that PC1 scores for manifest HD patients show a 
linear correlation with UHDRS scores, while pre-manifest HD patients appear to be an interim 
group between healthy controls and manifest HD patients in the LD space, suggesting that SERS 
may be useful for defining disease onset. 
CONCLUSION 
In conclusion, using both a RS and SERS analytical approach to study the serum samples of 
HD patients, we have demonstrated that SERS is better suited as a novel and robust tool by 
which to detect molecular changes related to disease onset and progression in HD. In particular, 
various patient characteristics (eg. age, genetic status and DB scores) along with clinical scores 
(e.g. Indp, TFC, FA and UHDRS) show linear correlations to the specific spectral intervals of RS 
and/or SERS spectra. While RS is capable of measuring intrinsic patient characteristics such as 
the age and genetic predisposition (CAG repeat size), SERS offers a higher level of specificity 
with respect to disease status in HD patients including clinical scores. This indicates the presence 
of HD associated molecules at very low concentrations in the serum with a natural affinity for 
gold nanoparticles, and thus providing selectivity for detection using SERS. Overall, our findings 
suggest that SERS correlates well with established clinical assessments, while offering an easy, 
patient-friendly and objective assessment of HD state and stage. It therefore has the potential to 
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be used for the diagnosis of disease onset as well as being of value in tracking disease progress 
and response to disease-modifying therapies which are now starting to be trialled in the clinic.54 
 
EXPERIMENTAL SECTION 
Ethics and processing of human samples. All human samples were collected with informed 
consent under full ethical approval in accordance with the United Kingdom's Department of 
Health guidelines and local ethical approval (NRES Committee East of England - Cambridge 
Central, reference no. 96/085). Demographic profiles for all participants can be found in ESI 
Table S4. Blood was collected and serum samples were prepared by allowing the blood to clot at 
room temperature for 20 minutes, followed by centrifugation (2000xG) at 4°C for 20 minutes. 
Serum samples were either frozen at -20°C for storage or used fresh at 4°C within 6 hours of 
collection.  
Ethics and processing of animal samples. All animal procedures were performed in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and approved by the 
University of Cambridge Animal Welfare Policy. R6/1 transgenic mice were purchased from the 
Jackson Laboratory (USA) and the colony was maintained by backcrossing to C57BL/6 females 
purchased from Harlan Laboratories (UK). After the mice were weaned, tissue from ear biopsies 
was sent to Largen Inc. (USA) for genotyping. All animals were kept in a temperature and 
humidity-controlled (22 °C) room on a 12-hour light/dark cycle. The mice were separately 
housed in single-sex cages with 3–4 mice per cage. Water and food were made freely available 
in the home cage. Animals were culled using Schedule 1 methods at the specified age and, after 
sacrifice, blood was immediately collected via a heart puncture (mice) while serum samples were 
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prepared as described above. Brains were removed from the skull with the frontal cortex 
dissected and snap-frozen to -80°C before further processing. 
Agarose gel electrophoresis (AGERA). Crude tissue homogenates were prepared using a 
dounce homogeniser in 1% Triton X-100 plus cOmplete protease inhibitor cocktail (Roche). 
Homogenates were centrifuged (4000xG) at 4°C for 10 minutes, and electrophoresis was 
performed on a gel containing 1.8% agarose (Bioline) and 0.1% SDS (Sigma) dissolved in 
375mM Tris-HCl (pH 8.8). A total of 25μg of protein was loaded per well. The AGERA gel was 
run at 100V in Tris-glycine SDS running buffer and transferred in Tris-glycine transfer buffer at 
15 V at 4°C. Immunoblotting was performed using the mouse monoclonal MW8 antibody 
(1/1000, DSHB) against mutant huntingtin protein. 
RS and SERS experiments. All experiments were performed using a Renishaw® inVia 
Raman microscope with 633 and 785 nm HeNe and diode lasers, typically ≈1 mW. 
For RS experiments, 10 μl of serum was placed on the surface of a gold-coated (200 nm 
vapour deposited; surface roughness <1 nm) silicon wafer and covered with a small glass 
coverslip (Ø13 mm) to limit evaporation during the measurements. A gold-coated wafer was 
used to provide a smooth reflective surface to increase path length and hence, Raman signal 
collection. Raman spectra in the range of 200-2000 cm-1 were acquired in point scan mode using 
a x50 working objective and an exposure time of 15 seconds. A grating of 1200 lines/mm was 
used with an appropriate edge filter. Excitation of Raman modes was with 633 and 785 nm HeNe 
and diode lasers, typically ≈1 mW. 
 For SERS experiments, 1 ml of citrate-capped, spherical gold nanoparticles (Ø 40 nm, 9∙10-
10 particles/ml, 2.96∙10-4 M of gold/l, BBI Solutions, UK) was centrifuged (15 min at 10,000 
r/pm) and 980 μl of supernatant was removed. 5 μl of the concentrated AuNPs were pre-
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aggregated by mixing with 1μl of 10x concentrated phosphate buffered saline (Sigma) and then 
mixed with 5 μl of patient serum. After 30 min of incubation, aggregated AuNPs were spun 
down (30s at 8,000 r/pm) and the mixture was pipetted onto a glass slide and covered by a glass 
coverslip. All SERS experiments were performed using a Renishaw® inVia Raman microscope 
with a 633 nm laser in streamline mode for map scans (pixel size: 600 nm x 600 nm). A Leica 
100x (NA = 0.85) objective was used. Measurements on larger AuNPs clusters were carried out 
in line mapping (StreamLine©) using a collection time of 15-20 s per line over a spectral range of 
400-2200 cm-1. The excitation intensity was ~2∙104 W/cm2. Wire 3.4 software was used for data 
acquisition and initial processing. 
Data analysis. Exported raw spectra from map scans were background subtracted using 
MATLAB 2017a as done previously16-18 following z-score standardization prior to PCA and 
PCA-LDA analysis. 
The correlation of RS/SERS results with clinical measures (Fig. 5-7) was achieved by 
regression analysis of grouped PC1 scores of the RS and SERS spectra with disease features of 
HD patients. Due to the complexity of the RS/SERS as well as clinical patient data, a 
methodology was developed to identify correlations between these seven assessment categories 
and the PC1 scores, which were calculated for spectral intervals of 50 cm-1.  This spectral 
segmentation allows for the identification of significant peaks. Following the initial PCA 
analysis, PC1 scores of HD patients were split evenly into four groups for each disease feature. 
PC1 scores of healthy participants formed a separate group, except for the patient’s age, where 
five groups were chosen without a distinction between HD and healthy participants. ANOVA 
with post-hoc Bonferroni correction for multiple comparisons were generated for each group as 
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FIGURE AND LEGENDS 
 
Fig. 1 Methodology with RS and SERS. (A) An incident laser light interacts with the 
characteristic vibrations of the molecules (coloured symbols) in the sample (here illustrated for a 
drop of blood serum) resulting in Raman scattering which is then detected as a spectrum (B). 
While all molecules in the bulk of the sample can be interrogated with RS, only molecules in the 
direct vicinity of gold nanoparticles (AuNPs) (grey spheres) contribute to the SERS signature. 
Signals in SERS (B, black spectrum) are orders of magnitude stronger than in RS (B, blue 





Fig. 2 Tracking the progression of HD in cortical homogenates (A-B) and serum of transgenic 
R6/2 mice with SERS (C). (A) The AGERA shows both an increase in mutant Huntingtin 
aggregate size and intensity in the cortex of R6/2 mice as disease progresses. (B) Using a PCA 
approach we were able to separate WT littermates from transgenic littermates at 12 weeks of 
age; PC1 scores generated from SERS spectra of cortical homogenates of the R6/2 mice at 
different disease stages showed a similar progression profile to AGERA analysis. (C) Using a 
SERS approach on the serum, LD1 scores also correlated with the disease progression. Box and 





Figure 3: PC1 vs. PC2 scores represented as a scatter plot for RS (A) and SERS (B) analysis of 
serum from HD patients and healthy participants (ctrl) using the full spectral range (RS: 200-
1900 cm-1, SERS: 400-1900 cm-1). (C-D) PC1 scores were used to compute the p value for group 
segregation between genotype (blue) and gender (red), to indicate spectral intervals of significant 
group segregation for RS (C) and SERS (D). The significance level of p = 0.05 is indicated by an 




Fig 4 Average RS (A) and SERS (B) spectra of serum from healthy control subjects (blue lines) 
and HD patients (red line) as well as their standard deviations (C and D, respectively). The 
different spectra of the averages for RS (black line, E) and SERS (black line, F) are within the 
standard deviation (C and D) of the average spectra (A and B). Hence, LD loadings for each of 
the spectral methods, respectively (coloured line in E and F), are also taken into account 
alongside the explained variance of the underlying PC1 scores (colouration of LD loadings line, 





Fig. 5 The colour map shows the linear correlation of PC1 scores for spectral RS intervals 
(50 cm-1, x-axis) with different clinical HD assessment parameters (y-axis). High correlation is 
observed with patient’s age (650-700 cm-1, 1750-1880 cm-1), DB (1600-1650 cm-1), CAG repeat 
size (300-350 cm-1, 1750-1850 cm-1) and TFC (1200-1250 cm-1). The aR2 of the linear fit is 
colour-coded for each spectral interval and clinical parameter. Darker red colouration suggests 




Fig. 6 The colour map shows the linear correlation of PC1 scores for SERS intervals (50 cm-1, 
x-axis) with different clinical HD assessment parameters (y-axis). PC1 scores from SERS were 
highly correlated with Indp levels (1300-1350 cm-1), CAG repeat length (1600-1650 cm-1), DB 
scores (700-750 cm-1), FA scores (1300-1350 cm-1), TFC (1300-1350 cm-1) and UHDRS motor 
scores (1200-1250 cm-1). The aR2 of the linear fit is colour-coded for each spectral interval and 




Fig. 7 Grouped UHDRS motor scores vs PC1 scores (A) and LD1 scores (B) from the combined 
SERS spectral region 1200-1300 cm-1 and 1600-1700 cm-1. (A) A linear curve (aR2UHDRS = 0.97) 
has been fitted to the PC1 scores of manifest HD groups (UHDRS ≥ 5), which also has a good 
correlation for the pre-manifest group (UHDRS < 5). (B) In contrast, the LD1 scores 
significantly distinguishes (pcontrol-HD < 0.001) the control group from all four manifest HD 
groups, while the pre-manifest HD group appears to occupy a transitional state between the 
healthy controls and manifest HD subjects. 
 
